Bridge to Seed 2026
Myria Biosciences is building a platform that uses AI & designer microbes to create new natural-product-inspired molecules for medicine, unlocking a vast new chemical space for drug discovery.
The company already has early industry traction is raising a CHF 300k bridge round ahead of seed.
If interested, get in touch to learn more:
Steven Schmitt, CEO
+41 61 551 03 80
steven.schmitt@myria.bio
More information